A new UK start-up company, TopiVert, is set to receive £8 million in venture capital from the Imperial Innovations Group Plc and SV Life Sciences. TopiVert will develop topical drugs for inflammatory diseases of the eye and gut.
Scientists working for Addex Pharmaceuticals Ltd of Switzerland have reported discovering an apparently novel interaction between two members of the G-protein coupled receptor (GPCR) family which may have implications for the treatment of diabetes.
CircuLite Inc, which is preparing to launch in Europe what is said to be the world’s smallest blood pump, has raised $30 million in a Series D financing from a syndicate of venture capitalists led by Forbion Capital Partners and new investor Ronald O. Perelman.
ArGEN-X BV of the Netherlands, which is developing monoclonal antibodies against human disease, has raised €27.5 million in a Series B round to support the development of its preclinical portfolio of products which are based on natural antibodies from the llama.
AstraZeneca Plc has announced the allocation of an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. The fund invests in private life science companies.
Sapiens Steering Brain Stimulation GmbH of Munich, Germany and Eindhoven, the Netherlands has raised €10 million in additional funding to support development of its brain stimulation technology for Parkinson’s disease and other neurological disorders.
Galapagos NV has become the latest company to report positive clinical data for an oral Janus kinase (JAK) inhibitor in rheumatoid arthritis, an autoimmune disease that is estimated to affect about 1% of the world’s population. Current treatments include non-steroidal anti-inflammatory drugs; methotrexate, and biologic medicines.
UCB SA of Belgium has acquired, for an undisclosed sum, research assets from venture-capital backed Lectus Therapeutics Ltd of the UK as well as rights to the company’s technology platform for ion channel discovery.
The European Medicines Agency’s main scientific committee, the CHMP, has recommended that Caprelsa (vandetanib), a treatment for aggressive and symptomatic medullary thyroid cancer, be granted a conditional marketing authorisation.
The US Food and Drug Administration has approved a new treatment for acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer. The drug, Erwinaze (asparaginase Erwinia chrysanthemi), is from EUSA Pharma Inc.